Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population
- PMID: 40099810
- DOI: 10.1177/13524585251316474
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population
Abstract
Background: Retrospective studies did not show strong evidence of higher risk of adverse neonatal or pregnancy outcomes in women with multiple sclerosis (MS) compared to general population, but there are contradictory data on prematurity, cesarean section, and small birthweight for gestational age (SGA).
Methods: We compared pregnancy and birth outcomes in MS women included in RESPONSE, a French prospective cohort, with a recent survey (Enquête Nationale Périnatale (ENP)) describing leading indicators in perinatal epidemiology in France.
Results: On 7 April 2023, 476 pregnancies (461 MS women, 482 expected newborns) from RESPONSE were available. The ENP study reported 12,723 women and 12,939 expected newborns in March 2021. MS patients were older (mean age 32.6 ± 4.4 vs. 30.9 ± 5.3 years, p < 0.001), with similar rate of cesarean (23.8% vs. 21.4%, p = 0.115) and use of locoregional analgesia (86.6% vs. 85.1%, p = 0.51). Preterm birth was less frequent (4.0% vs. 7.0%, p = 0.001). Birthweight of children from MS mothers was similar to general population (3240 ± 477.2 vs. 3264.5 ± 552.9 g, p = 0.22), with slightly more children with SGA (13.4% vs. 9.8%, p = 0.04).
Conclusion: This prospective and contemporary comparison of pregnancy in MS women and the French population provides reassuring results. In the future, we need to assess the impact of disease-modifying treatment exposure during conception.
Keywords: Multiple sclerosis; cesarean section; locoregional analgesia; pregnancy; preterm.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Maillart reports research support from Biogen and ARSEP foundation and personal fees for lectures and advisory boards from Biogen, Janssen, Merck, Novartis, Roche, Sanofi, and Teva.Mr. Rollot has no financial disclosure to declare.Dr. Leray has received consulting and lecturing fees, and travel grants from Alexion, Merck, Novartis, Roche, and Sanofi.Mr. Benyahya has no financial disclosure to declare.Dr. Bourre has received consulting and lecturing fees, travel grants, and unconditional research support from Alexion, Biogen, Horizon, Janssen, Merck, Novartis, Roche, Sandoz, and SanofiDr. Carra-Dallière has received consulting, lecturing fees, and travel grants from Alexion, Biogen, Merck, Novartis, Roche, and Sanofi.Dr. Casey has no financial disclosure to declare.Dr. Deiva has received consulting and lecturing fees, travel grants, and consulting fees for advisory boards from Alexion, Biogen, Horizon, Novartis, Roche, and Sanofi.Mrs. Girod has no financial disclosure to declare.Dr. Guennoc has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Merck, Sanofi, and Roche.Dr. Marignier has received personal fees from Horizon Therapeutics, Alexion, Roche, and UCB and non-financial support from Horizon Therapeutics, Merck, Biogen, and Roche, outside the submitted work.Dr. Labauge has received grants and support for travels from Biogen, Novartis, Merck, Roche, Sanofi Genzyme, Teva, and AlexionDr. Bensa has received consulting fees, and travel grants from Alexion, Janssen, Merck, Novartis, Roche, and Sanofi.Dr. de Seze has no financial disclosure to declare.Dr. Berger has received consulting and lecturing fees, travel grants from Alexion, Biogen, Merck, Novartis, Roche, and Sanofi.Dr. Biotti has received consulting and lecturing fees, travel grants, and unconditional research support from Alexion, Biogen, Horizon, Janssen, Merck, Novartis, Roche, Sandoz, and SanofiDr. Bresch reports consulting and lecturing fees, and travel grants from Roche, Sanofi, Merck, Biogen, Janssen, BMS, Novartis, and Sandoz.Dr. Thouvenot reports consulting and lecturing fees, travel grants, or unconditional research support from the following pharmaceutical companies: Actelion, Biogen, Merck, Novartis, Roche, Sanofi, and Teva; has a patent pending for biomarkers of neurodegeneration and neuroregeneration and a patent pending for a diagnosis method of multiple sclerosis (EP18305630.8); and received academic research support from PHRC, ANR, EDMUS Foundation, and ARSEP Foundation.Dr. Moreau has no financial disclosure to declare.Dr. Derache has received personal compensation and lectures fees, travel grants, and consulting fees for advisory boards from Biogen, Bristol Mayer, Janssen, Merck Novartis, Roche, and Sandoz.Dr. Zéphir has received consulting and lecturing fees and travel grants from Horizon Therapeutics, Alexion, Bms, Roche, Sanofi, Merck, Novartis, and Biogen Idec out of this work.Dr. E Le Page reports research support from Biogen Idec and personal fees for lectures and advisory boards from Biogen Idec, Janssen, Merck, Novartis, Roche, Sanofi, and Teva.Pierre Clavelou has received personal consulting fees from Biogen, Janssen, Merck, Novartis, Roche, Sanofi, Teva, and support for attending meetings and/or travel from Janssen, Merck, Novartis, and Sanofi.Dr. Casez reports personal fees from Biogen, Roche, Merck, Novartis, Janssen, and Sanofi, and travel grants from Roche, Merck, and Novartis.Dr. Laplaud served on scientific advisory boards for Alexion, BMS, Roche, Sanofi, Novartis, Merck, MSD, Janssen, and Biogen, received conference travel support and/or speaker honoraria from Alexion, Novartis, Biogen, Roche, Sanofi, BMS, and Merck, and received research support from Fondation ARSEP, Fondation EDMUS, Association Notre Sclerose, and Agence Nationale de la Recherche.Dr. Kwiatkowski has received consulting, lecturing fees, and travel grants from Biogen, Biogen, Janssen, Merck, Novartis, Sanofi, and Roche.Dr. Grosset-Janin has no financial disclosure to declare.Dr. Pittion-Vouyovitch has received consulting and lecturing fees from Alexion, Biogen, Merck, Novartis, Sanofi, Roche, and TevaDr. Ruet has received personal fees from Biogen, Alexion, Novartis, Sanofi, Horizon therapeutics, and Merck; travel grants from Biogen, Alexion, Novartis, Sanofi, and Merck; and research support from Biogen, BMS, Sanofi, Roche, and Merck.Dr. Dos Santos has received consulting and lecturing fees, travel grants, and unconditional research support from Alexion, Biogen, Janssen, Merck, Novartis, and Sanofi.Dr. Robert-Varvat has received consulting and lecturing fees and travel grants from Biogen, Novartis, Janssen, Novartis, Roche, Merck, and SanofiDr. Morel has no financial disclosure to declare.Dr. Lebrun-Frenay has no financial disclosure to declare.Dr. Vukusic has received consulting and lecturing fees, travel grants, and unconditional research support from Biogen, Janssen, Merck, Novartis, Roche, Sandoz, and Sanofi.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
